No meaningful signal from this cluster — the sales are minor and likely part of pre-arranged 10b5-1 plans; the rest are standard compensation events. Traders should focus on clinical or regulatory developments rather than this activity.
Price Chart
Executive Summary
A cluster of insider transactions at Alnylam Pharmaceuticals over the past week includes open-market sales by the CSO and EVP of R&D totaling $204K, alongside non-cash grant and derivative exercise events involving top executives including the CEO and CFO. The sales are small in absolute value and represent a negligible fraction of the company's $43.4B market cap, while the other transactions are routine equity compensation activities.
Key Financial Metrics
Key Facts
- CSO Kevin Fitzgerald sold $91,483 in shares (289 shares at $316.55) on March 3, 2026
- EVP of R&D Pushkal Garg sold $112,443 in shares (355 shares at $316.74) on March 3, 2026
- CEO Yvonne Greenstreet received a non-cash award of 13,844 shares and exercised 5,921 shares via derivative on February 27 and March 2
- CFO Jeffrey Poulton and other C-suite executives received non-cash awards and exercised derivatives with no open-market impact
- Total open-market sales in cluster: $204K, representing just 0.0005% of Alnylam's $43.4B market cap
Financial Impact
$204K in open-market sales, 0.0005% of market cap — immaterial
Risk Factors
- Perception of insider selling ahead of a potential downturn, though magnitude is too small to support concern
- Future dilution from equity grants, though typical for biotech firms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (10 trades, 7d window) | cluster-ALNY-1772673102389 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Court Ruling | $224.60 $238.27 | ▲ +6.09% | ▲ +8.06% | $226.93 (+1.04%) |
Jul 30, 2026 9w ago | 8-K | $205.48 $236.56 | ▼ −15.13% | ▼ −11.16% | $226.93 (−10.44%) |
Jul 29, 2026 9w ago | Institutional Cluster | $286.62 $239.00 | ▼ −16.61% | ▼ −21.63% | $226.93 (−20.83%) |
Mar 3, 2026 30w ago | Insider Cluster | $318.65 $330.87 | ▲ +3.83% | ▲ +8.24% | $226.93 (−28.79%) |
Mar 3, 2026 30w ago | Insider Cluster | $318.65 $330.87 | ▲ +3.83% | ▲ +8.24% | $226.93 (−28.79%) |
Feb 28, 2026 30w ago | Institutional Cluster | $325.07 $316.09 | ▼ −2.76% | ▲ +5.18% | $226.93 (−30.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access